Cellectar Biosc (CLRB)

$0.29 -0.07 (-20.16%)
Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
MSG8898
MSG8898 Sep. 12 at 7:24 PM
$CLRB I believe that yesterday AM a news about a partnership leaked and someone started to buy big spiking the stock price. Then they realized that the partnering was about radio-supply, and the stock price settled. You got a bunch of and idea of where the SP could go in a few minutes if the right news hits. IMO, there are still two weeks to go before some decent news starts to show up, but IMO we won't see the partnering news until 12 months trial data is out.
0 · Reply
dogood
dogood Sep. 12 at 1:11 PM
$CLRB will there be big run today?
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 11 at 4:53 PM
$RADX Significant Radiopharma deals in 2025 $CSBR $CLRB $NVS
0 · Reply
EvenBetter99
EvenBetter99 Sep. 11 at 3:54 PM
$CLRB small float
0 · Reply
Ulong
Ulong Sep. 11 at 12:25 PM
$CLRB "Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225" https://investor.cellectar.com/press-releases/detail/373/cellectar-biosciences-and-itm-enter-supply-agreement-for
1 · Reply
Slab6
Slab6 Sep. 11 at 12:25 PM
$CLRB https://www.cellectar.com/news-media/press-releases/detail/373/cellectar-biosciences-and-itm-enter-supply-agreement-for
0 · Reply
stockflashj
stockflashj Sep. 11 at 12:10 PM
$CLRB interesting spike this am
0 · Reply
higgggghhhher
higgggghhhher Sep. 10 at 10:38 PM
$CLRB hopefully the board and management is weighing in the world going to shit and opting to just sell the company so we can at least enjoy it for a lil while
1 · Reply
elmono
elmono Sep. 10 at 8:02 PM
$CLRB $PEPG nice f’ing sell off today 👏👏👏👏
0 · Reply
Jeanvaljean4
Jeanvaljean4 Sep. 9 at 9:46 PM
Update - My biotech portfolio : $FBIO (35%) $SKYE (25%) $NRXP (25%) $CLRB (15%)
1 · Reply
Latest News on CLRB
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 11, 2025, 8:05 AM EDT - 2 days ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 9, 2025, 8:05 AM EDT - 4 days ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 5, 2025, 8:45 AM EDT - 8 days ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Sep 3, 2025, 8:05 AM EDT - 10 days ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 27, 2025, 8:05 AM EDT - 17 days ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 12:25 PM EDT - 4 weeks ago

Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 7:19 AM EDT - 4 weeks ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Aug 7, 2025, 8:05 AM EDT - 5 weeks ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 2, 2025, 4:15 PM EDT - 2 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jul 1, 2025, 9:25 AM EDT - 2 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 26, 2025, 8:05 AM EDT - 2 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 24, 2025, 8:30 AM EDT - 2 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Jun 18, 2025, 4:30 PM EDT - 3 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 11, 2025, 8:05 AM EDT - 3 months ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 5, 2025, 9:00 AM EDT - 3 months ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Jun 4, 2025, 8:05 AM EDT - 3 months ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:17 PM EDT - 4 months ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 7:05 AM EDT - 4 months ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

May 7, 2025, 8:05 AM EDT - 4 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 4 months ago

Cellectar Announces Plan to Explore Strategic Alternatives

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 6 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 13, 2025, 7:05 AM EDT - 6 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Mar 5, 2025, 8:05 AM EST - 6 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:05 AM EST - 7 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Jan 12, 2025, 6:00 PM EST - 8 months ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 11, 2024, 11:25 AM EST - 9 months ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Dec 10, 2024, 5:00 PM EST - 9 months ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 21, 2024, 8:00 AM EST - 10 months ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 10:59 AM EST - 10 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 18, 2024, 7:05 AM EST - 10 months ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 14, 2024, 8:05 AM EST - 10 months ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 12, 2024, 8:05 AM EST - 10 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 11, 2024, 4:05 PM EST - 10 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 7, 2024, 6:40 AM EST - 11 months ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Nov 1, 2024, 5:00 PM EDT - 11 months ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 26, 2024, 6:40 AM EDT - 1 year ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 1:25 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 13, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Aug 8, 2024, 5:15 PM EDT - 1 year ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 24, 2024, 3:22 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 3:09 PM EDT - 1 year ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 10:49 AM EDT - 1 year ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Jun 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 29, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

May 20, 2024, 1:02 PM EDT - 1 year ago

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

May 14, 2024, 1:05 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

May 14, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

MSG8898
MSG8898 Sep. 12 at 7:24 PM
$CLRB I believe that yesterday AM a news about a partnership leaked and someone started to buy big spiking the stock price. Then they realized that the partnering was about radio-supply, and the stock price settled. You got a bunch of and idea of where the SP could go in a few minutes if the right news hits. IMO, there are still two weeks to go before some decent news starts to show up, but IMO we won't see the partnering news until 12 months trial data is out.
0 · Reply
dogood
dogood Sep. 12 at 1:11 PM
$CLRB will there be big run today?
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 11 at 4:53 PM
$RADX Significant Radiopharma deals in 2025 $CSBR $CLRB $NVS
0 · Reply
EvenBetter99
EvenBetter99 Sep. 11 at 3:54 PM
$CLRB small float
0 · Reply
Ulong
Ulong Sep. 11 at 12:25 PM
$CLRB "Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225" https://investor.cellectar.com/press-releases/detail/373/cellectar-biosciences-and-itm-enter-supply-agreement-for
1 · Reply
Slab6
Slab6 Sep. 11 at 12:25 PM
$CLRB https://www.cellectar.com/news-media/press-releases/detail/373/cellectar-biosciences-and-itm-enter-supply-agreement-for
0 · Reply
stockflashj
stockflashj Sep. 11 at 12:10 PM
$CLRB interesting spike this am
0 · Reply
higgggghhhher
higgggghhhher Sep. 10 at 10:38 PM
$CLRB hopefully the board and management is weighing in the world going to shit and opting to just sell the company so we can at least enjoy it for a lil while
1 · Reply
elmono
elmono Sep. 10 at 8:02 PM
$CLRB $PEPG nice f’ing sell off today 👏👏👏👏
0 · Reply
Jeanvaljean4
Jeanvaljean4 Sep. 9 at 9:46 PM
Update - My biotech portfolio : $FBIO (35%) $SKYE (25%) $NRXP (25%) $CLRB (15%)
1 · Reply
dogood
dogood Sep. 9 at 12:31 PM
$CLRB great news
0 · Reply
ObsOlet
ObsOlet Sep. 9 at 12:16 PM
$CLRB https://www.cellectar.com/news-media/press-releases/detail/372/cellectar-biosciences-to-participate-at-oppenheimer-3rd
1 · Reply
ObsOlet
ObsOlet Sep. 9 at 6:31 AM
$CLRB New Company Presentation is online! https://www.cellectar.com/news-media/presentations
0 · Reply
CasperPuff
CasperPuff Sep. 8 at 10:15 PM
$CLRB
0 · Reply
makedatbread88
makedatbread88 Sep. 8 at 4:21 PM
$CLRB buying here has multiple conferences this month floats getting locked it looks like bottom is $4.70 people are loading here this can run hard at any time between now and years end
0 · Reply
DM0n3y
DM0n3y Sep. 8 at 3:22 PM
$CLRB
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 8 at 4:18 AM
$CLRB Great piece that accurately captures CLRB's current position. So if you want to refresh your understanding of CLRB or learn about CLRB for the first time, this is essential reading. https://beyondspx.com/quote/CLRB/analysis/cellectar-biosciences-unlocking-radiopharmaceutical-value-through-precision-targeting-clrb
0 · Reply
ObsOlet
ObsOlet Sep. 5 at 1:03 PM
$CLRB And for October (13-17).....maybe the most important Presentation: "13th International Workshop on Waldenström’s Macroglobulinemia"
2 · Reply
EvenBetter99
EvenBetter99 Sep. 5 at 1:02 PM
$CLRB The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications. Sounds good, with new fda regulatory even better. 🚀🚀🚀
0 · Reply
ObsOlet
ObsOlet Sep. 5 at 12:54 PM
$CLRB 5 presentations at 4 different congresses in September! Wow - top https://www.cellectar.com/news-media/press-releases/detail/371/cellectar-biosciences-to-participate-in-multiple-upcoming
0 · Reply
dogood
dogood Sep. 5 at 12:48 PM
$CLRB will it run now
0 · Reply
EvenBetter99
EvenBetter99 Sep. 4 at 7:20 PM
$CLRB To date, the Company has focused on rare cancers with significant unmet need including WM, MM, sarcomas, and HGG, among others. new FDA pathway is like a gold medal for clrb PDC Technology.
0 · Reply